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Aminoglycoside-freeinterventionalantibioticmanagement
in patients undergoing haemopoietic stem cell
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Aminoglycosid-freies interventionelles Antibiotikamanagement bei
Patienten mit hämopoetischer Stammzelltransplantation
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Zusammenfassung
Die Bedeutung der Aminoglycoside für das empirische antibiotische
Management in der Frühphase nach Stammzelltransplantation ist mit
AusnahmedesRisikosschwererNierenschädennichtvollständiggeklärt.
Zur Klärung dieser Frage wurden die Daten der Frühinfektion von 152
Patienten mit 195 allogener und autologer Stammzelltransplantation
analysiert.DieProphylaxeundTherapiederInfektionenerfolgtegemäß
internationalen Standards mit der einzigen Ausnahme, dass auf den
Einsatz von Aminoglycosiden verzichtet wurde, um ototoxische und
nephrotoxische Risiken zu vermeiden und dem Selektionsdruck mit
VerbreitungresistenterErregerzubegegnen.DieEinsparungvonKosten
war ein zusätzlicher Aspekt.
Die Inzidenz der Frühinfektion betrug 78% (152/195). 67 Patienten
waren von mehr als einer Infektionsepisode betroffen, wobei Fieber
unklarer Genese und Bakteriämie/Septikämie dominierten. Auf das
interventionelle Regime mit β-Lactam oder Carbapenem + Glyopeptide
reagierten 48% der Patientrn. Aminoglycoside wurden nur bei drei Pati-
enteninderSpätphasederErkrankungverabfolgt.DieMortalitätbetrug
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verursacht durch Schimmelpilze, assoziiert. Der Vergleich mit der Lite-
ratur ergibt keinen Anhalt für eine Unterlegenheit des Aminoglycosid-
freienAntibiotika-ManagementsfürPatientenmitStammzelltransplan-
tation.DamitstütztdievorliegendeStudiedieMöglichkeitdesVerzichts
auf Aminoglycoside in der Therapie der Frühinfektion von Patienten mit
Stammzelltransplantation zur Vermeidung toxischer Risiken.
Introduction
Infectionscontributesignificantlytomorbidityandmortal-
ityafterstemcelltransplantation[1],[2],[3].Thediagno-
sis of neutropenic fever demands immediate onset of
broad-spectrum antibiosis and rapid escalation in the
caseofnon-response[4],[5].Additionofasystemicanti-
mycotic compound effective against Candida spp. and
moulds is recommended within 48 to 96 hours after ini-
tiation of first line antibiotic administration, if fever has
notresolved.Aminoglycosideshavebeenastandarddrug
fortherapyofneutropenicfeverforseveralyearsbecause
of suggested additional clinical activity i.e. synergistic
effectsincombinationwithβ-lactamantibiotics;however,
considerable adverse effects are nephrotoxicity and oto-
toxicity [6], [7].
Allogeneicandautologousstemcelltransplantationhave
emerged during the last two decades and can currently
applied to patients older than seventy and to heavily pre-
treated patients with partly impaired organ functions [8],
[9], [10]. Additionally, nephrotoxic cytostatics such as
cisplatinumareessentialcomponentsofsomehigh-dose
protocolstogainoptimalanti-tumoureffectsagainstmale
germ cell cancer [11]. Especially in multiple myeloma,
renalfunctionmaybeimpairedduetounderlyingdisease.
In the allogeneic setting an immunosuppressive therapy
withcyclosporine-Aortacrolimusismandatorytoprevent
graft rejection and graft-versus-host disease [8], [9]. Ad-
ministration of drugs such as foscarnet, trimethoprim-
sulfmethoxazoleoracyclovirforanti-infectiousprophylaxis
or therapy after transplantation can be associated with
considerable nephrotoxicity or it may require a normal
renal function [12].
The position of aminoglycosides in first line antibiotic
therapy of high-risk patients with neutropenic fever has
been discussed controversial. Some trials show equality
ofmonotherapywithbroadspectrumβ-lactamcompared
to aminoglycoside-containing combination therapy [13],
[14], [15]. Other investigators used quinolones as com-
binationpartnerforβ-lactamsinsteadofaminoglycosides
[16],however,thispolicyislimitedinstemcelltransplant-
ation since most patients here receive quinolones for
antibacterial prophylaxis [12]. Marie et al. described in
their meta-analysis significant advantages when
aminoglycosides are used [17]: The rate of defeveres-
cence was higher, the duration of fever shorter, less
vancomycin was needed, and the overall success-rate
was higher. As a consequence, most guidelines recom-
mend both, single β-lactam therapy or combination with
aminoglycosideforinterventionalantibiosisinneutropenic
patients [4], [5].
To address the important issue of nephroprotection by
avoidanceofaminoglycosidesinstemcelltransplantation,
anaminoglycoside-freeinterventionalantibioticmanage-
ment for therapy of neutropenic fever or early infections
ofpatientsundergoinghaemopoieticcelltransplantation
has been conducted at Greifswald University Hospital
since 1996. Results of this study are presented and dis-
cussed here.
Patients and methods
Patients,diagnosesandtransplantations
The present investigation followed a retrospective longi-
tudinal surveillance protocol. Surveillance data were
createdinroutinecooperationwithanexternprofessional
infectioncontrolpractitionerfromtheInstituteofHygiene
and Environmental Medicine.
Between 1996 and 2004 a total of 152 patients under-
went 195 transplant procedures after written informed
consent. In 48 cases (24.6%) the recipient received an
allograft from a matched related donor (n=21; 10.8%) or
from an unrelated donor (n=27; 13.8%). In the latter
situation, maximal one HLA-antigen mismatch was ac-
cepted. In 147 cases (75.4%) the transplantation was
carried out with G-CSF-mobilised autologous stem cells.
43transplantationsweresecondorthirdtransplantations.
Thirty subsequent autologous transplantations were
performed as part of a therapy protocol, mainly for male
germ cell cancer or for multiple myeloma. Thirteen sub-
sequent allogeneic transplantations were carried out for
salvagetherapyofrelapseddisease.Eachtransplantation
was considered as a separate patient in this analysis for
statistical reasons. 121 (62.1%) patients were male and
74 (37.9%) were female. The median patient age was
50.7 years (median; range: 17.3–70.7) years.
Indications for stem cell transplantation were acute and
chronicleukaemias(n=40;20.5%),malignantlymphomas
(n=55; 28.2%), multiple myeloma (n=35; 17.9%), myelo-
dysplastic syndrome (n=6; 3.1%), and solid tumours
(n=59; 30.3%). Details are shown in Table 1. Stem cell
transplantation was performed in 124 cases (63.6%) in
the early course of disease (first complete or partial re-
mission, first chronic phase of CML, or transplantation
as a part of the primary treatment). The remaining 71
transplantations (31.4%) were done in more advanced
disease.
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Conditioning regimen was busulphan-based in 81 cases
(41.5%).25patients(12.8%)receivedtreosulphan/fluda-
rabine prior to allogeneic transplantation. VIC was given
ashigh-dosetherapypriortoautologousstemcellreinfu-
sion in 35 cases (18.0%) and high-dose melphalan was
given for multiple myeloma in 31 cases (15.9%). Total
body irradiation in conjunction with chemotherapy was
used in 6 cases (3.1%) and one patient (0.5%) received
an allogeneic stem cell boost without prior conditioning.
HaemopoiesiswasstimulatedwithG-CSFaftertransplant-
ation until engraftment.
Prophylaxis of GvHD in the allogeneic setting was with
cyclosporine-A and short course methotrexate or my-
cophenolate-mofetil, depending on the conditioning
therapy. 29/48 patients (60.4%) undergoing allogeneic
transplantationweretreatedwithantithymocyteglobulin.
Metronidazolewasgivenforanaerobicgutdecontamina-
tion in the allogeneic setting.
Antimicrobial prophylaxis
Allogeneic transplantations were done in rooms condi-
tioned with HEPA-filtrated air (H 13 point use of filters) in
our transplant unit. Autologous transplantations were
also conducted in these rooms. Only when no HEPA-con-
ditioned room was available, patients in the autologous
setting were nursed in single-rooms on the normal ward.
Antimicrobial prophylaxis was initiated lately with begin
of conditioning therapy [12]. In most cases (n=171;
87.7%) a third-generation quinolone was given, in four
cases combined with a β-lactam active against gram-
positive bacteria. Eight transplantations (4.1%) in the
autologous setting were conducted without antibacterial
prophylaxis. The remaining 17 patients received miscel-
laneous antibiotics, mainly β-lactams, for prophylaxis.
Fluconazole was given for systemic antimycotic prophy-
laxis in 127 cases (65.1%) and 64 patients (32.8%) re-
ceived itraconazole. In six of these cases the initial drug
wasswitchedduringfurthercoursetoitraconazole(n=2),
fluconazole (n=2), or conventional amphotericin-B (0.2
mg/kg/d). One patient each received voriconazole,
caspofungin or conventional amphotericin-B (0.2
mg/kg/d), or was transplanted without antimycotic
prophylaxis. Amphotericin-B suspension was given orally
at least four times daily upon tolerability. Reasons for
discontinuation were emesis or mucositis.
Pneumocystisjiroveciiprophylaxiswasdonewithmonthly
pentamidine-inhalations after an initial loading dose
(n=87;44.6%)orwithtrimethoprim-sulfmethoxazolethree
times per week (n=18; 9.2%). The remaining 90 patients
(46.2%)weremanagedwithoutPneumocystis-prophylaxis.
Pneumocystis-jirovecii-prophylaxis was mandatory in all
patients undergoing allogeneic transplantation and de-
pended upon the therapy-protocol in the autologous set-
ting.
A total of 80 patients received either acyclovir (n=79;
40.5%) or foscarnet (n=1; 0.5%) for antiviral prophylaxis.
It was mandatory in allogeneic transplantation. Patients
undergoingautologousstemcelltransplantationreceived
prophylactic virustatics only as a secondary prophylaxis,
uponregulationsofatherapyprotocoloriftheunderlying
disease was Hodgkin’s lymphoma.
Antibacterial prophylaxis was stopped after the onset of
antibiotic therapy and antimycotic prophylaxis after the
onset of systemic antifungal therapy for suspected or
documented infection.
Diagnosis of infection
Diagnosis of fever of unknown origin (FUO) was made
after the occurrence of a body temperature of ≥38.2°C.
Resolution of fever was defined as the first of three days
with a maximum temperature of 37.5°C. Site specific
infections were diagnosed according to the results of
clinical examinations or the results obtained by specific
diagnostic procedures.
Antimicrobial therapy
Broad spectrum antibiotic therapy was started immedi-
atelywhenthetemperatureroseabove38.2°Corhigher,
or for documented or suspected bacterial infection (e.g.:
positive x-ray examination, clinical and local signs of in-
fection). Additionally, a significant increase of CRP to at
leastca.60mg/lintheearlyormiddlephaseofexpected
neutropenia was – in conjunction with clinical perform-
ance – an indication for antimicrobial escalation. Blood
cultures were drawn prior to antibiotic therapy and then
daily until the fever resolved. X-ray examination of the
chestwascarriedout.Urineculture,oral,rectalandnose
swabs were taken prior to antibiotics and serologic tests
for Aspergillus or Candida antigen were performed when
a mycotic infection was suspected. Special diagnostic
procedures such as computed tomography x-ray, bron-
chioalveolar lavage or obtaining tissue biopsies were
carried out when necessary.
First line antibacterial therapy consisted of a β-lactam
with activity against Pseudomonas spp. Generally,
ceftazidime was the first drug given, only in cases where
cisplatinumwaspartofhigh-doseregimentheantimicro-
bialtherapywasbegunwithimipenem/cilistatin.Incases
with increased risk factors for Gram-positive infections
vancomycin or teicoplanin was added initially. Factors to
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tionwereaseveremucositis,asuspectedCVL-associated
sepsis, known colonisation with MRSA or Streptococcus
pneumoniaeoracriticalillpatient[4],[18].Antimicrobial
therapy was modified or escalated when fever did not
respond within 24 to 48 hours. The kind of modification
depended upon the clinical course and the results of mi-
crobial and other laboratory investigations. First modifi-
cationwassupplementationwithaglycopeptid,whennot
part of initial therapy. Next steps were either the change
oftheinitiallygivenβ-lactamortheadditionofamacrolid-
antibiotic or the escalation of antifungal therapy. Since
less toxic antimycotics became available during the time
of observation, there was a trend to escalate earlier with
newer substances such as liposomal amphotericin-B,
modernazolesorechinocandinesthanwithconventional
amphotericin-B. Clinical signs suggestive of mycosis in-
cludedfeverorpulmonaryinfiltratesthatdidnotrespond
to antibiotics or a suspicious CT-scan of the lung.
Further modifications of antimicrobial therapy such as
fosfomycin or clindamycin for treatment of soft tissue in-
fections were made according to the results of surveil-
lanceculturesandserologicaltests,andfromtheclinical
features and course of infection.
Antiviral therapy with ganciclovir or foscavir was initiated
after diagnosis of viral infection by culture or molecular
methods, or in the case of clinical evidence of viral infec-
tion. In case of a suspected Herpes simplex or Varicella
zoster virus reactivation, acyclovir was either initiated,
dose-increased or replaced by another virustatic.
Antibacterial and antimycotic therapy was discontinued
when the patient had recovered with his neutrophile
granulocytes(>1/nl)andsignsofinfectionandfeverhave
completely resolved.
Data collection and analysis
Data were collected with database software Access
(Microsoft, Munich, Germany) and analysed using the
computer software Excel (Microsoft, Munich) and
GraphPad Prism for Windows (GraphPad Software, San
Diego, California, USA). The independent T-test or the
Mann-WhitneyU-testwasusedforthecomparisonoftwo
groups,anddatasetswithmorethantwosubgroupswere
compared by variate analysis (LSD/Bonferroni).
Results
Engraftment, neutropenia and
graft-versus-host disease (GvHD)
Patients undergoing autologous transplantation were
slightlyolderthanthoseundergoingallogeneictransplant-
ation (median 52.5 years; range: 17–71 vs. median 47.5
years; range: 18.5–65; p<0.05, Mann-Whitney U-test).
187 patients engrafted with 0.5 leukocytes/nl between
day 0 (cells never below 0.5L/nl) and day +25 (median
day +9) after transplantation. 1.0 leukocytes/nl were
reached by 185 patients also on day +9 (median; range:
0–27 days). Engraftment of leukocytes was significantly
faster after autologous stem cell transplantation than
after allografting: 0.5L/nl: 8 days (median; range: 0–12
days) vs. 12 (median; range: 0–25 days) (p<10
-9, Mann-
Whitney U-test); 1.0L/nl: 9 days (median; range: 7–14)
vs.13(median;range:0–27days)(p<10
-10,Mann-Whitney
U-test). 16/48 (25%) patients after allogeneic stem cell
transplantation suffered from moderate to severe acute
graft-versus-host disease (stage 2: n=6; stage 3: n=9;
stage 4: n=1).
Fever and infections
Preliminaryitmustberemarked,thatnotallpatientswith
aninfectiondevelopedfeverandthatfromsomepatients
with positive microbial results more than one pathogen
was isolated. As the consequence, the congruency of
results needs not necessarily to be 100%.
124 patients developed at least one episode of fever
during stem cell transplantation without differences
between allogeneic and autologous patients. Median
onsetoffeverwasday+6(range:–1–47).Feveroccurred
significantly early in the autologous setting (median on
day +5.5, range: –1–14) compared to day +7.5 (median,
range: –1–47) in the allogeneic setting. Fever resolved
after three days (median; range: 1–29) without differ-
ences between both modalities.
Asecondepisodeoffeveroccurredmorefrequentlyafter
allogeneictransplantation(12/48)thanafterautologous
transplantation (16/147), p<0.02, chi-square. As a con-
sequence, the cumulative duration of fever was signifi-
cantly longer after allogeneic transplantation than after
autologoustransplantation(median6days;range:1–56
vs.3days,range:1–24;p<0.001;Mann-WhitneyU-test).
A total of 152 (77.9%) patients developed at least one
episode of infection under stem cell transplantation. An
overview of observed infections gives Table 2. Most fre-
quent primary manifestation of infection was fever of
unknown origin (FUO) with 74 cases (37.9%) followed by
microbiologically confirmed bacteriaemia with or without
signs of sepsis (n=26; 13.3%). Seventeen (8.7%) infec-
tionswererelatedtothecentralvenousline.Urinarytract
was focus of primary infection in 9 cases (4.6%) followed
by pneumonitis and enteritis (8 cases each, 4.1%). Other
diagnoses like infection of the central nervous system or
soft tissue not related to the CVL were rare.
The analysis of subsequent (non-first) infections gave a
lesscleargraduation:Mostfrequentwasenteritis(n=17;
11.2%) followed by bacteriaemia with or without signs of
sepsis (n=17; 11.2%). 43 patients (22.1%) passed pro-
cedure of stem cell transplantation without any signs of
infection.
Microbial pathogens
Isolated microbial pathogens are shown in Table 3. The
microbes were only considered after isolation from non-
natural sites. In total, 63 pathogens were isolated from
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Table 3: Isolated microbial pathogens
the first episodes of infection and 43 from subsequent
episodes. The predominant bacteria in the first episode
were coagulase-negative staphylococci (CoNS) (n=16;
25.9%), followed by enterobacteriacaeae (n=9; 14.3%)
and enterococci (n=7; 1.1%). C. difficile was identified in
6 cases (9.5% of isolates). Aspergillus spp. was isolated
inthreecases(4.8%),oneisolateofFusariumsolaniiand
one isolate of Candida non-albicans (1.6%, each) were
found. Pseudomonas spp. and other non-fermentative
Gram-negative rods represent 2 (3.2%) and 3 (4.8%) of
isolated pathogens from first infections, respectively.
Further details are given in Table 3.
Between the first to subsequent infection a decrease of
the number of pathogens and different changes of the
prevalence of the species could be observed. The most
important change can be referred to CoNS – with 10%
decrease. In this context it must be necessarily pointed
out, that in cases with identification of Pseudomonas
spp. as the pathogenic agent, the clinical signs of infec-
tion have resolved prior to availability of microbiological
results. The proportion of virus isolates increased from
10 to 14%. Please refer to Table 3 for further details.
Response to therapy
Since an initiated interventional antibiosis was discon-
tinued after engraftment and resolution of infection and
in not all cases with more than one episode of infection
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be clearly discriminated, only the definite resolution of
infection was analysed.
A total of 155 patients received antimicrobial therapy for
documentedorsuspectedinfection(Table4).74patients
(47.7%) responded to therapy with ceftazidime or imi-
penem/cilistatin or meropenem in combination – either
initially or sequentially – with a glycopeptid (vancomycin
or teicoplanin). In 34 cases (21.9%) the resolution of in-
fection could be clearly related to engraftment of leuko-
cytes. Antimycotic therapy was successful in 6 patients
(3.9%). In 11 cases (7.1%) no response to antimicrobial
therapy was seen and the response could neither be
correlated to a distinct drug nor to engraftment in 10
cases (6.5%).
Table 4: Response to antimicrobial therapy. N=40 patients
without antimicrobial were not included in this analysis.
Another view was to correlate the response of infection
tothestepofantimicrobialescalation:76patients(49%)
responded to steps one and two of antibacterial escal-
ation and n=10 (6.5%) to the third step followed by anti-
mycosis (n=6; 3.9%). Only 3 patients (1.6%) responded
after a further (4
th) antibacterial line.
Outcome
137 patients undergoing 180 transplantations (92.3%,
related to transplantations) were discharged or trans-
ferred to another ward and 15 patients (7.7%) have died
at median on day +20 (range: 3–130 days) after stem
cell transplantation (Table 5). The interval showed highly
significantdifferencesbetweenpatientsundergoingallo-
geneic transplantation compared to patients after auto-
logous transplantation. Discharge, transfer or death was
at median on day +17 (range: 6–116) after autologous
and on day +38 (range: 3–130) after allogeneic trans-
plantation (p<10
-10, Mann-Whitney U-test).
Three patients died after autologous and 12 after allo-
geneic transplantation. The majority of these patients
were heavily pre-treated and 10/15 patients were trans-
planted in higher (>2
nd) remission or with active disease.
Additionally, for six of these patients it was a second
transplantation. The death could be clearly related to an
infection in 9/15 cases (60%).
Aspergillusspp.wasculturallyidentifiedasthepathogen
in 4/9 (44.4%) infection-related deaths and in one other
case clinical course and CT-scan of the lung made the
diagnosis of an invasive mycosis probable. Five other
patients have died from sepsis; however, here the micro-
bial pathogens remained unknown. The remaining five
patients have died from acute GvHD (n=1), relapse of
malignancy alone (n=2) or relapse with pulmonary
bleeding (n=1) and from a cerebral (n=1) bleeding. All
together, 7 of these 15 patients (46.7%) had severe
complications which could not be correlated to infection
(Table 5).
Discussion
The present retrospective analysis investigates the effi-
cacy of an ‘aminoglycoside-free’ interventional antibiotic
regimen for the therapy of infections in the acute phase
ofpatientsundergoingallogeneicorautologoushaemopoi-
etic cell transplantation. Aminoglycosides were not ex-
cludedbyastudy-protocol;however,itwaspolicytoavoid
them whenever possible because of their considerable
side effects. Varying Medline-searches revealed surpris-
ingly, that the newest publications investigating early in-
fections in stem cell transplantation patients in general
have been published approximately 10 years ago.
Overall, 77.9% (n=152) of the patients developed signs
of infection. Neutropenic fever and bacteriaemia or sep-
ticaemia represented 54.8% of infections and 22.1% of
all patients remained free of signs of infection. The dur-
ationofafirstepisodeoffeverwasatmedian3daysand
themediancumulativedurationoffeverwas3daysafter
autologous and 6 days after allogeneic transplantation.
These results are not different to those from preceding
publications, where the use of aminoglycosides was
usual. Krüger et al. reported similar results in 1999 [3]:
about 60% of infections in their investigation were FUO
andsepticaemia.Cumulativedurationoffeverwasinthe
present investigation slightly shorter than in the cited
(Table6).Comparisonofthepresentresultswithpreced-
ing studies is hampered by at least two facts: In the
nineties was the use of marrow harvests common and
nowadays the use of growth-factor mobilised stem cells
is the standard. One result of this shift is a shorter dur-
ation of neutropenia: The engraftment was reported in
1999 at median on day +17 compared to day +9 in the
present investigation [3]. Second, the percentage of allo-
grafts and autografts varies between publications [2],
[3], [19]. However, since it has been accepted that infec-
tions in the pre-engraftment phase are comparable in
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both settings two additional publications were available
for comparison [2], [19].
The present investigation gives no hint for emerging of
Gram-negative bacteria when aminoglycosides are
avoided. More than 25% of all isolated pathogens were
Gram-positivecocci.Enterobacteriacaeae,Pseudomonas
spp. and other non-fermentative rods represent here
23.6% of isolated pathogens comparing to 21.4% in a
previous publication [3]. In contrast Offidani et al, who
have used aminoglycosides in first line antibiosis, re-
ported 36.2% Gram-negative rods between isolated
pathogens [19].
The overall response rate to first and second line inter-
ventional antibiosis was approximately 50% and only
slightly increased by supplementation with antimycotics.
Thisobservationcouldbearesultofimprovedantimycotic
prophylaxis. Only 65% of the patients in the present in-
vestigation received fluconazole alone and all other pa-
tients received a substance active against Aspergillus
spp. and Candida non-albicans. In contrast, flucanozole-
prophylaxiswasstandardintheearlynineties.Thecumu-
lative response rate to antimicrobial therapy was 64.5%
and again comparable to the results published by the
other groups (Table 6) [2], [3], [19].
Three patients have died after autologous stem cell
transplantation from multi-organ failure and sepsis
without isolation of any pathogen. Krüger et al. reported
in 1999 also three early deaths after autologous trans-
plantation(3/157;1.9%)[3].Kolbeetal.[2]andOffidani
etal.[19]reportednodeaths,howeveranearlymortality
of 2% (3/148 patients) is within international standard.
Furthermore, one of these patients suffered additionally
from chemotherapy-related CNS-toxicity. Mortality after
allogeneictransplantationcouldonlybecomparedtothe
results from Krüger from 1999, since the other publica-
tionswererestrictedtotheautologoussetting.Theactual
mortality rate was 25% compared to 15.1% in 1999 [3].
However, here it is necessary to mention the high risk
profile of the patients which underwent allogeneic trans-
plantation and have died during procedure (Table 5).
Furthermore, the rate of unrelated donors in the allo-
geneic setting was actually 56.3% compared to 22.5% in
the preceding presentation. Even this analysis gave no
hintforanincreasedcontributionofEnterobacteriacaeae
or non-fermentative Gram-negative rods to mortality.
In conclusion, the presented data support the concept
of an ‘aminoglycoside-free’ interventional antibiotic
management despite the fact, that quinolones are not
availableasareasonablecombinationpartnerforempiric
therapy since their use is common in prophylaxis [12]. In
comparison to other investigators no increase of infec-
tions, of Gram-negative pathogens or hints for an inferior
outcome were observed. The investigation of a potential
benefit of aminoglycosides in the setting of stem cell
transplantation within a prospectively randomised trial
would normally be the next step, however, conducting
such a trial would aggravated by the fact that transplant
patients are very heterogeneously. As the consequence,
the presented results encourage the use of an
‘aminoglycoside-free’ antibiotic management since con-
siderable side effects can be avoided [16], [20].
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